Biotech Fluidics, in collaboration with Sahlgrenska Science Park, has officially launched Ventri Labs AB (VentriLabs), a spinout company advancing patented technology for the gentle pumping of biological fluids.

Based at Sahlgrenska Science Park in Gothenburg, VentriLabs will be part of the CO-AX accelerator program, benefiting from access to health innovation labs, a vibrant entrepreneurial community and tailored business support.

Dr Robin Öz, CEO of VentriLabs, says, “Leveraging the support provided by Sahlgrenska Science Park and CO-AX, we are off to a great start. With our robust intellectual property portfolio, we are well positioned to establish new collaborations with partners and investors to bring our transformative technology to market.”

Annica Grimberg Lignell, Head of CO-AX Accelerator at Sahlgrenska Science Park, added, “We are excited to support VentriLabs in their journey to revolutionize biological fluid handling. Their innovations not only improve pumping precision, but they also have the potential to save lives.”

About VentriLabs

VentriLabs is a pioneering Biotech and MedTech company, focused on innovative solutions in flow control and fluid transfer. The company develops systems for gentle handling of delicate fluids. Offering liquid flow with high precision and sensitivity combined with great versatility, VentriLabs´ innovative pump technology excels across a multitude of technologies, ranging from general laboratory use and bioprocessing to clinical systems utilizing extracorporeal blood circulation. The company is based in Gothenburg, Sweden and is a subsidiary of Biotech Fluidics. More information – www.ventrilabs.com.

About Sahlgrenska Science Park

Sahlgrenska Science Park is dedicated to enhancing the competitiveness of West Sweden’s life science sector. By actively fostering health innovation and catalyzing collaboration, we’re helping to shape the future of healthcare. More information – www.sahlgrenskasciencepark.se